Abstract As increasing numbers of broadly neutralizing monoclonal antibodies (mAbs) against HIV-1 enter clinical trials. it is becoming evident that combinations of mAbs are necessary to block infection by the diverse array of globally circulating HIV-1 strains and to limit the emergence of resistant viruses. Multi-specific antibodies. in which two or more HIV-1 entry-targeting moieti... https://www.spidertattooz.com/Venture-Pouch/